Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Official title: MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project (Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk Stratification, Diagnosis and Management of the Disease)
Run by M.D. Anderson Cancer Center · NCT06878144 · Data updated 2026-11-12
This study collects and stores blood, tissue, BAL fluid, and related data from adults with cancer who have or are at risk for mucormycosis or other fungal infections to help understand the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | October 20, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2032 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT06878144 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18-100) with cancer who have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or risk for fungal infection and who are willing to undergo routine diagnostic procedures.
✕Probably not a fit
Patients without mucormycosis or related risk who do not contribute to the identified data sets may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational program at MD Anderson Cancer Center. It prospectively identifies and collects clinical samples from high-risk adults with proven or probable mucormycosis, invasive aspergillosis, bacterial pneumonia, or risk for fungal infection, and stores these samples for analysis. Participants are grouped into four cohorts based on infection status and undergo routine diagnostic procedures as part of standard care. The project also gathers relevant host samples and annotates clinical information about the course and outcomes of mucormycosis cases and controls.
Why it matters
Potential benefit: If successful, the project could improve understanding of mucormycosis and related infections, informing future diagnostics and treatments.
How similar studies have gone: Prior observational efforts in fungal infections have generated valuable specimen repositories and clinical annotations, suggesting potential utility for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection. * Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care. Exclusion Criteria: • Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.
Where it's running
-
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Dimitrios Kontoyiannis, MD — M.D. Anderson Cancer Center
- Study coordinator: Dimitrios Kontoyiannis, MD
- Email: dkontoyi@mdanderson.org
- Phone: (713) 792-0826
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific 3D-printed titanium implants for facial reconstruction
This study tests whether custom-made 3D-printed titanium facial implants can improve reconstruction and appearance for adults with facial bone defects or asymmetry.
-
Monitoring isavuconazole levels in children with invasive fungal infections
This study is testing how well isavuconazole works in children with serious fungal infections by checking their blood levels to make sure they are getting the right amount of the medicine.
-
Blood biomarkers to help diagnose invasive mucormycosis
This project will test a blood biomarker that looks for unique fungal sugars to see if it can detect invasive mucormycosis in patients with suspected infection, compared with high-risk patients without infection and patients with other fungal infections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.